MARKET OUTLOOK The HIV therapy market is crowded with many approved antiretroviral (ARV) therapies. Growth in this market is being driven by increasing acceptance of new, high-priced ARVs,…
*NOTE: the brochure was already reviewed by an editor* MARKET OUTLOOK Idiopathic pulmonary fibrosis (IPF) is a type of lung disease characterized by the thickening and stiffening of tissues in…
In 2020, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $120 billion in the major pharmaceutical markets under study (United…
Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have moved earlier in the disease spectrum to…
In 2020, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…
In 2020, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $100 billion in the major pharmaceutical markets under study (United…
In 2020, sales of branded biologics in ophthalmology reached over $8.56 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2020-2030 forecast period,…
In 2020, sales of branded biologics for respiratory indications reached nearly $1.5 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029…
In 2020, sales of insulins at the ex-manufacturer price level exceeded $11 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2020-2030 forecast…
In 2020, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled almost $4.18 billion in the major pharmaceutical markets under study (…
In 2020, sales of branded MAb biologics in oncology exceeded $30 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $3…
In 2020, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $100 billion in the major pharmaceutical markets under study (United…
In 2019, sales of insulins at the ex-manufacturer price level exceeded $11 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029 forecast…
In 2019, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled almost $3.98 billion in the major pharmaceutical markets under study (…